Watch out Amgen and Teva, Eli Lilly got its green light for a rival CGRP migraine drug — and they’re coming after you
Eli Lilly has just scored the third FDA OK for a CGRP migraine drug, and now the pharma giant is setting out to leapfrog the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
